CNS Pharmaceuticals Inc. [NASDAQ: CNSP] price surged by 14.68 percent to reach at $0.32. The company report on December 18, 2020 that CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced it will host a conference call and live webcast on December 18th, 2020 at 8:30am ET to discuss its Investigational New Drug (IND) approval for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM), and planned Phase 2 Berubicin clinical trial.
Details of the webcast are below:.
A sum of 9327078 shares traded at recent session while its average daily volume was at 63.86K shares. CNS Pharmaceuticals Inc. shares reached a high of $2.98 and dropped to a low of $2.30 until finishing in the latest session at $2.50.
Guru’s Opinion on CNS Pharmaceuticals Inc. [CNSP]:
Ladenburg Thalmann have made an estimate for CNS Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 24, 2020.
The Average True Range (ATR) for CNS Pharmaceuticals Inc. is set at 0.26 The Price to Book ratio for the last quarter was 16.67, with the Price to Cash per share for the same quarter was set at 0.07.
CNSP Stock Performance Analysis:
CNS Pharmaceuticals Inc. [CNSP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.57. With this latest performance, CNSP shares gained by 16.08% in over the last four-week period, additionally plugging by 9.17% over the last 6 months – not to mention a drop of -40.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNSP stock in for the last two-week period is set at 59.06, with the RSI for the last a single of trading hit 59.46, and the three-weeks RSI is set at 58.54 for CNS Pharmaceuticals Inc. [CNSP]. The present Moving Average for the last 50 days of trading for this stock 2.08, while it was recorded at 2.36 for the last single week of trading, and 2.36 for the last 200 days.
Insight into CNS Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for CNSP is now -104.03, given the latest momentum, and Return on Invested Capital for the company is -109.96. Return on Equity for this stock declined to -109.96, with Return on Assets sitting at -90.22.
Reflecting on the efficiency of the workforce at the company, CNS Pharmaceuticals Inc. [CNSP] managed to generate an average of -$775,442 per employee.CNS Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.
CNSP Stock EPS
With the latest financial reports released by the company, CNS Pharmaceuticals Inc. posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -466.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNSP.
CNS Pharmaceuticals Inc. [CNSP] Insider Position Details
There are presently around $0 million, or 0.70% of CNSP stock, in the hands of institutional investors. The top three institutional holders of CNSP stocks are: ESSEX INVESTMENT MANAGEMENT CO LLC with ownership of 61,563, which is approximately -13.472% of the company’s market cap and around 0.90% of the total institutional ownership; MORGAN STANLEY, holding 12,500 shares of the stock with an approximate value of $27000.0 in CNSP stocks shares; and INTEGRATED ADVISORS NETWORK LLC, currently with $23000.0 in CNSP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in CNS Pharmaceuticals Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 4 institutional holders increased their position in CNS Pharmaceuticals Inc. [NASDAQ:CNSP] by around 21,236 shares. Additionally, 3 investors decreased positions by around 10,561 shares, while 5 investors held positions by with 72,697 shares. The mentioned changes placed institutional holdings at 104,494 shares, according to the latest SEC report filing. CNSP stock had 2 new institutional investments in for a total of 16,460 shares, while 2 institutional investors sold positions of 976 shares during the same period.